COSM

EX-99.1

2 cosm_ex991.htm

PRESS RELEASE

cosm_ex991.htm

EXHIBIT 99.1

Cosmos Health Reports Q1 2026 Results: Revenue Up 31% to $17.9M, New Q1 Record; Total Liabilities Reduced by $4.5M; Stockholders' Equity Up 7.6%; Cash of $2.2M; Record Momentum Continues into Q2 with U.S. Expansion Underway

· Record Q1 revenue of $17.9M, up 31% from $13.71 million in Q1 2025, reflecting strength across all core segments

· Total liabilities decreased by $4.5M, or 9.6%, driven by a substantial reduction in convertible note and credit facility balances

· Stockholders' equity increased by $1.4M, or 7.6%, with the liabilities-to-assets ratio improving by 370 basis points

· Adjusted EBITDA near breakeven as increased revenue was offset by strategic investments to support global growth

· Record momentum continues into Q2 2026 with U.S. expansion actively underway

CHICAGO, IL / ACCESS Newswire / May 21, 2026 / Cosmos Health Inc. (“Cosmos Health” or the “Company”)(NASDAQ:COSM), a diversified, vertically integrated global healthcare group, today reported financial results for the first quarter ended March 31, 2026.

First Quarter 2026 Financial Highlights

Income Statement

Cosmos Health delivered the highest Q1 revenue in Company history with continued progress toward adjusted profitability, reflecting broad-based commercial strength — over 75 new pharmacies added at CosmoFarm, growing Sky Premium Life order activity across multiple markets, and expanded contract manufacturing agreements at Cana Laboratories.

·

Revenue was $17.93 million, an increase of 30.7% from $13.71 million in Q1 2025, reflecting strong sales momentum across all core divisions.

○

Adjusted revenue was $18.40 million, up 34.2% year-over-year, reflecting a $470,601 sales discount reversal.

·

Gross profit was $1.38 million in Q1 2026, compared to $2.05 million in Q1 2025, reflecting a revenue mix shift toward wholesale distribution activity at CosmoFarm, compounded by the aforementioned sales discount adjustment.

○

Adjusted gross profit was $1.85 million, reflecting the sales discount reversal applied to revenue.

·

Total operating expenses increased to $3.57 million in Q1 2026, compared to $2.88 million in Q1 2025, reflecting strategic investments in personnel, infrastructure, technology, and AI-driven efficiencies to support global growth initiatives.

1

·

Net income (loss) was ($2.81 million) in Q1 2026, compared to ($0.82 million) in Q1 2025. The increase is driven principally by $1.15 million of non-cash, non-operational items:

○

$390,350 in non-cash interest on convertible facilities

○

$442,439 in digital asset mark-to-market losses

○

$313,157 in foreign currency translation losses

·

Adjusted EBITDA was ($229,596) in Q1 2026, near breakeven, as increased revenue was offset by higher expenses reflecting the Company's ongoing investments in global growth initiatives.

·

Adjusted Net Income (Loss) was ($996,502), driven by $766,906 in interest expense incurred in support of the Company's growth investments.

Balance Sheet

Cosmos Health continued to improve its balance sheet in Q1 2026, with active debt reduction and working capital optimization driving an improvement in the liabilities-to-assets ratio to 68.2% from 71.9% at year-end 2025.

·

Total assets were $62.37 million as of March 31, 2026, compared to $65.48 million at December 31, 2025, reflecting a diversified asset base with solid liquidity, a strong inventory position, and a significant real estate and intellectual property portfolio.

○

Liquid assets totaled $4.3 million, comprising cash and cash equivalents of $2.2 million as well as digital assets and marketable securities of $2.1 million.

·

Total liabilities decreased by $4.51 million, or 9.6%, to $42.54 million as of March 31, 2026, from $47.05 million at December 31, 2025, driven by a substantial reduction in convertible note and credit facility balances.

·

Total stockholders' equity increased by $1.40 million, or 7.6%, to $19.83 million as of March 31, 2026, up from $18.42 million at December 31, 2025.

Management Commentary

Greg Siokas, CEO of Cosmos Health, stated: “Q1 2026 was a record Q1 for Cosmos Health, with revenue of $17.93 million, up 31% year-over-year and 34% on an adjusted basis, reflecting broad-based commercial momentum across every major division — record distribution volumes at CosmoFarm, continued global expansion of Sky Premium Life, and new contract manufacturing agreements at Cana Laboratories.

This momentum is continuing into Q2 2026, and we are focused on sustaining it well beyond this year. We believe Cosmos Health is entering a new phase of growth, driven by strategic investments across our organization — in personnel, facilities, infrastructure, technology, and AI-driven efficiencies — to support our global expansion plans, strengthen our R&D pipeline, and build the foundation for long-term sustainable value creation. A key pillar of this growth is our entry into the lucrative U.S. nu

EX-99.1

2 cosm_ex991.htm

PRESS RELEASE

cosm_ex991.htm

EXHIBIT 99.1

Cosmos Health Reports Full Year 2025 Results: Revenue Hits All-Time Record of $65.3M, Up 20%; Gross Profit Surges 83% to $7.9M; Gross Margin Expands 418 Basis Points; Adjusted EPS Improves 82%; Cash Position Up 10x to $3.5M; Record Growth Continues Into 2026 Across All Core Segments

· Scaled contract manufacturing division, securing long-term agreements for over 12 million units

· Expanded Sky Premium Life portfolio by 60 SKUs and accelerated global expansion, securing purchase orders for over 300,000 units across new markets

· Advanced R&D pipeline, securing patented anticancer drugs, multiple AI-driven patent filings, and CCX0722 weight management product entering final development

· Secured $300 million financing facility to launch digital asset treasury strategy

· CEO Greg Siokas increased ownership by over 3.3 million shares, reinforcing deep insider conviction

· Strong momentum continues into 2026 with record growth across all core segments and continued U.S. expansion underway

CHICAGO, IL / ACCESS Newswire / April 15, 2026 / Cosmos Health Inc. (“Cosmos Health” or the “Company”)(NASDAQ:COSM), a diversified, vertically integrated global healthcare group, today reported financial results for the full year ended December 31, 2025, delivering the strongest annual revenue performance in the Company’s history.

Full Year 2025 Financial Highlights

Performance was marked by all-time high revenue, significant gross profit expansion, and margin improvement, driven by strong performance across core business segments, including scaling the contract manufacturing division at Cana Laboratories, increased volumes in the CosmoFarm wholesale distribution business supported by an expanded pharmacy network, solid sales growth through Decahedron in the United Kingdom, and the global expansion of proprietary brands, including Sky Premium Life and C-Scrub.

Key Metric

FY 2025

FY 2024

Change

(in $)

Revenue

65,271,815

54,426,402

+20 %

Gross Profit

7,895,575

4,311,323

+83 %

Gross Margin

12.10 %

7.92 %

+418 basis points

Adjusted EBITDA

(3,361,385 )

(3,438,975 )

2% improvement

Adjusted Net Income (Loss) per Share

(0.12 )

(0.65 )

+82 %

Cash & Cash Equivalents

3,459,893

315,105

+998 %

Total Assets

65,477,518

54,311,892

+21 %

1

Income Statement

·

Revenue increased by 20% to $65.27 million in FY 2025, compared to $54.43 million in FY 2024, representing the highest annual revenue in Company history and reflecting strong performance across all core divisions.

·

Gross profit increased by 83% to $7.90 million, compared to $4.31 million in FY 2024, driven by improved product mix, increased contribution from higher-margin divisions, and operational efficiencies.

·

Gross margin expanded to 12.10%, compared to 7.92% in FY 2024, representing a 418-basis point improvement.

·

Total operating expenses increased to $24.60 million, compared to $19.86 million in FY 2024, reflecting strategic investments in talent and new hires, including managerial, sales, and scientific personnel, corporate growth initiatives supporting global expansion, as well as extensive provisions for doubtful accounts.

○ Excluding provisions for doubtful accounts and other non-cash items, operating expenses remained broadly in line with the prior year.

·

Total other income (expense), net, was ($2.44 million) in FY 2025, compared to ($0.64 million) in FY 2024, largely reflecting non-cash items, including mark-to-market losses on digital assets, non-cash interest expense, and changes in the fair value of convertible notes.

·

Net income (loss) was ($19.14 million), compared to ($16.18 million) in FY 2024.

·

Adjusted EBITDA improved to ($3.36 million), compared to ($3.44 million) in FY 2024, driven by stronger gross profitability and adjustments for non-cash and non-recurring items.

·

Adjusted net income (loss) was ($5.98 million), compared to ($4.45 million) in FY 2024, primarily reflecting higher costs associated with business expansion and growth initiatives.

·

Net income (loss) per share improved significantly, with reported net loss per share of ($0.63) compared to ($1.17) in 2024, while adjusted net income (loss) per share improved to ($0.12) from ($0.65) in the prior year.

Balance Sheet

Cosmos Health maintained a robust financial foundation, expanding its asset base and enhancing liquidity. The Company ended the year with a solid cash position to support growth initiatives.

· Total assets increased to $65.48 million, compared to $54.31 million as of December 31, 2024, reflecting growth across core business segments and expanded operational scale, supported by the following key components:

○ Property and equipment, net, totaled $10.58 million, largely reflecting the Company’s wholly owned real estate assets, including CosmoFarm’s logistics center and Cana Laboratories’ manufacturing facilities.

○ Cash and cash equivalents totaled $3.46 mi

cosm_8k.htm0001474167false00014741672025-11-172025-11-17iso4217:USDxbrli:sharesiso4217:USDxbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported) November 17, 2025

Cosmos Health Inc.

(Exact name of registrant as specified in its charter)

Nevada

000-54436

27-0611758

(State or other jurisdiction of incorporation)

(Commission File Number)

(I.R.S. Employer Identification No.)

5 AGIOU GEORGIOU, Pilea, Thessaloniki, Greece

55438

(Address of principal executive offices)

(Zip Code)

Registrant’s telephone number, including area code (312) 865-0026

(Former name or former address, if changed since last report.)

Title of Each Class

Trading Symbol

Name of Each Exchange On Which Registered

Common Stock, $.001 par value

COSM

The Nasdaq Stock Market LLC

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13a-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

ITEM 2.02 RESULTS OF OPERATIONS AND FINANCIAL CONDITION.

On November 17, 2025, Cosmos Health Inc., a Nevada corporation (the “Company”), issued a press release announcing its financial results for the quarter and nine months ended September 30, 2025. A copy of the Company’s press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is hereby incorporated by reference in this Item 2.02.

ITEM 7.01 REGULATION FD DISCLOSURE.

The information set forth in Item 2.02 of this Current Report on Form 8-K is incorporated by reference in this Item 7.01.

In accordance with General Instruction B.2 to Form 8-K, the information set forth in the Items 2.02 and 7.01 and in Exhibit 99.1 hereto, shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, or otherwise subject to the liability of that section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, or the Securities Exchange Act of 1934, except as shall be expressly set forth by specific reference in that filing.

By furnishing this Current Report on Form 8-K, the Company makes no admission as to the materiality of any information in this Current Report on Form 8-K, including the statements made in Items 2.02 and 7.01 above and in Exhibit 99.1 hereto.

ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS

(d) Exhibits

Exhibit No.

Description

99.1

Press Release issued by Cosmos Health Inc., dated November 17, 2025.

104

Cover Page Interactive Data File (embedded within the Inline XBRL document)

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Company has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

COSMOS HEALTH INC.

Date: November 17, 2025 By: /s/ Georgios Terzis

Georgios Terzis

Chief Financial Officer

3